TriSalus Life Sciences, Inc.
TLSI
$4.76
$0.030.63%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 9.49% | -0.36% | -30.56% | 28.78% | 42.97% |
| Total Depreciation and Amortization | -21.35% | -20.51% | -15.86% | -6.98% | -0.97% |
| Total Amortization of Deferred Charges | 42.05% | 31.05% | 71.41% | 117.74% | 213.48% |
| Total Other Non-Cash Items | 7.92% | 451.37% | 770.71% | -15.76% | -39.36% |
| Change in Net Operating Assets | 85.58% | 110.25% | 121.66% | 150.14% | 67.41% |
| Cash from Operations | 19.63% | 42.01% | 55.90% | 52.08% | 48.53% |
| Capital Expenditure | 45.45% | 70.47% | -166.09% | -38.98% | -30.18% |
| Sale of Property, Plant, and Equipment | 0.00% | 0.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 47.62% | 73.31% | -142.90% | -26.99% | 47.83% |
| Total Debt Issued | -100.00% | -100.00% | -60.00% | -60.00% | -60.00% |
| Total Debt Repaid | 68.14% | 85.71% | 3.57% | -11.49% | -29.89% |
| Issuance of Common Stock | 45.07% | 400.18% | 36.84% | 89.97% | 334.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -12.69% | 91.55% | 79.95% | 80.10% | -101.57% |
| Cash from Financing | 8.84% | 42.62% | -18.91% | -4.30% | -43.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.31% | 378.44% | 466.36% | 214.05% | -21.05% |